Loading...

APC anti-mouse CD8a Antibody

Pricing & Availability
Clone
53-6.7 (See other available formats)
Regulatory Status
RUO
Other Names
T8, Lyt2, Ly-2
Isotype
Rat IgG2a, κ
Ave. Rating
Submit a Review
Product Citations
publications
53-6dot7_APC_041106
C57BL/6 mouse splenocytes were stained with CD8 (clone 53-6.7) APC (filled histogram) or rat IgG2a, κ APC isotype control (open histogram).
  • 53-6dot7_APC_041106
    C57BL/6 mouse splenocytes were stained with CD8 (clone 53-6.7) APC (filled histogram) or rat IgG2a, κ APC isotype control (open histogram).
Compare all formats See APC spectral data
Cat # Size Price Quantity Check Availability Save
100711 25 µg £23
Check Availability


Need larger quantities of this item?
Request Bulk Quote
100712 100 µg £72
Check Availability


Need larger quantities of this item?
Request Bulk Quote
Description

CD8, also known as Lyt-2, Ly-2, or T8, consists of disulfide-linked α and β chains that form the α(CD8a)/β(CD8b) heterodimer and α/α homodimer. CD8a is a 34 kD protein that belongs to the immunoglobulin family. The CD8 α/β heterodimer is expressed on the surface of most thymocytes and a subset of mature TCR α/β T cells. CD8 expression on mature T cells is non-overlapping with CD4. The CD8 α/α homodimer is expressed on a subset of γ/δ TCR-bearing T cells, NK cells, intestinal intraepithelial lymphocytes, and lymphoid dendritic cells. CD8 is an antigen co-receptor on T cells that interacts with MHC class I on antigen-presenting cells or epithelial cells. CD8 promotes T cell activation through its association with the TCR complex and protein tyrosine kinase lck.

Product Details
Technical Data Sheet (pdf)

Product Details

Verified Reactivity
Mouse
Antibody Type
Monoclonal
Host Species
Rat
Immunogen
Mouse thymus or spleen
Formulation
Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide.
Preparation
The antibody was purified by affinity chromatography, and conjugated with APC under optimal conditions.
Concentration
0.2 mg/ml
Storage & Handling
The CD8a antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze.
Application

FC - Quality tested
Recommended Usage

Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is ≤ 0.25 µg per 106 cells in 100 µl volume. It is recommended that the reagent be titrated for optimal performance for each application.

Excitation Laser
Red Laser (633 nm)
Application Notes

Clone 53-6.7 antibody competes with clone 5H10-1 antibody for binding to thymocytes3. The 53-6.7 antibody has been reported to block antigen presentation via MHC class I and inhibit T cell responses to IL-2. This antibody has also been used for depletion of CD8a+ cells. Additional reported applications (for the relevant formats) include: immunoprecipitation1,3, in vivo and in vitro cell depletion2,10,15, inhibition of CD8 T cell proliferation3, blocking of cytotoxicity3,4, immunohistochemical staining5,6 of acetone-fixed frozen sections and zinc-fixed paraffin-embedded sections, and spatial biology (IBEX)29,30. Clone 53-6.7 is not recommended for immunohistochemistry of formalin-fixed paraffin sections. The Ultra-LEAF™ purified antibody (Endotoxin < 0.01 EU/µg, Azide-Free, 0.2 µm filtered) is recommended for functional assays or in vivo studies (Cat No. 100746).

Application References

(PubMed link indicates BioLegend citation)
  1. Ledbetter JA, et al. 1979. Immunol. Rev. 47:63. (IHC, IP)
  2. Hathcock KS. 1991. Current Protocols in Immunology. 3.4.1. (Deplete)
  3. Takahashi K, et al. 1992. P. Natl. Acad. Sci. USA 89:5557. (Block, IP)
  4. Ledbetter JA, et al. 1981. J. Exp. Med. 153:1503. (Block)
  5. Hata H, et al. 2004. J. Clin. Invest. 114:582. (IHC)
  6. Fan WY, et al. 2001. Exp. Biol. Med. 226:1045. (IHC)
  7. Shih FF, et al. 2006. J. Immunol. 176:3438. (FC)
  8. Kamimura D, et al. 2006. J. Immunol. 177:306.
  9. Bouwer HGA, et al. 2006. P. Natl. Acad. Sci. USA 103:5102. (FC, Deplete)
  10. Kao C, et al. 2005. Int. Immunol. 17:1607. PubMed
  11. Ko SY, et al. 2005. J. Immunol. 175:3309. (FC) PubMed
  12. Rasmussen JW, et al. 2006. Infect. Immun. 74:6590. PubMed
  13. Lee CH, et al. 2009. Clin. Cancer Res. PubMed
  14. Geiben-Lynn R, et al. 2008. Blood 112:4585. (Deplete) PubMed
  15. Kingeter LM, et al. 2008. J. Immunol. 181:6244. PubMed
  16. Guo Y, et al. 2008. Blood 112:480. PubMed
  17. Andrews DM, et al. 2008. J. Virol. 82:4931. PubMed
  18. Britschqui MR, et al. 2008. J. Immunol. 181:7681. PubMed
  19. Kenna TJ, et al. 2008. Blood 111:2091. PubMed
  20. Jordan JM, et al. 2008. Infect. Immun. 76:3717. PubMed
  21. Todd DJ, et al. 2009. J. Exp. Med. 206:2151. PubMed
  22. Bankoti J, et al. 2010. Toxicol. Sci. 115:422. (FC) PubMed
  23. Medyouf H, et al. 2010. Blood 115:1175. PubMed
  24. Riedl P, et al. 2009. J. Immunol. 183:370. PubMed
  25. Apte SH, et al. 2010. J. Immunol. 185:998. PubMed
  26. Bankoti J, et al. 2010. Toxicol. Sci. 115:422. (FC) PubMed
  27. del Rio ML, et al. 2011. Transpl. Int. 24:501. (FC) PubMed
  28. Cui L, et al. 2015. J Control Release. 206:220. PubMed
  29. Radtke AJ, et al. 2020. Proc Natl Acad Sci U S A. 117:33455-65. (SB) PubMed
  30. Radtke AJ, et al. 2022. Nat Protoc. 17:378-401. (SB) PubMed
Product Citations
  1. Stone VM, et al. 2022. iScience. 25:105070. PubMed
  2. Zelenka T, et al. 2022. Nat Commun. 13:6954. PubMed
  3. Choi JG, et al. 2020. Front Immunol. 11:598556. PubMed
  4. Chang YS, et al. 2020. Int J Mol Sci. 21:00. PubMed
  5. Liu Y, et al. 2021. Cell Metabolism. 33(6):1221-1233.e11. PubMed
  6. Glasner A,et al. 2017. Sci Rep.. 10.1038/s41598-017-12998-w. PubMed
  7. Logan K Smith et al. 2018. Immunity. 48(2):299-312 . PubMed
  8. Schuster M, et al. 2017. J Immunol. 199:920. PubMed
  9. Li X et al. 2019. Immunity. 50(3):576-590 . PubMed
  10. O'Malley G, et al. 2018. Cancer Immunol Res. 1.240277778. PubMed
  11. Jiang W, et al. 2017. Sci Rep. 7:6501. PubMed
  12. Xu X, et al. 2020. Chin Med. 15:33. PubMed
  13. Bian L, et al. 2022. Front Immunol. 13:938598. PubMed
  14. Di Martile M, et al. 2020. J Immunother Cancer. 8:. PubMed
  15. Li X, et al. 2022. Nat Commun. 13:2794. PubMed
  16. Zhao X, et al. 2022. Front Mol Biosci. 9:786864. PubMed
  17. Jiang Q, et al. 2022. Theranostics. 12:59. PubMed
  18. Kim D, et al. 2021. Nanomicro Lett. 13:31. PubMed
  19. Renrick AN, et al. 2021. Front Immunol. 607044:12. PubMed
  20. Paris J et al. 2019. Cell Stem Cell. 25(1):137-148 . PubMed
  21. Espinosa-Cueto P, et al. 2017. PLoS One.. 10.1371/journal.pone.0182126. PubMed
  22. Rodriguez-García A, et al. 2021. Nat Commun. 12:877. PubMed
  23. Pan Y, et al. 2021. Front Cell Neurosci. 15:664312. PubMed
  24. Hewitson JP, et al. 2020. J Immunol. 204:2949. PubMed
  25. Xu ZH, et al. 2021. Mediators Inflamm. 2021:8856326. PubMed
  26. Jiang W, et al. 2021. Oncol Lett. 22:625. PubMed
  27. Chen L, et al. 2022. Mol Ther Oncolytics. 24:522. PubMed
  28. Li ZX, et al. 2022. Arch Virol. :. PubMed
  29. Ghosh S, et al. 2022. APL Bioeng. 6:036105. PubMed
  30. Bauer KM, et al. 2022. JCI Insight. 7:. PubMed
  31. Ma Z, et al. 2016. Clin Cancer Res. 22: 2969 - 2980. PubMed
  32. Iwasaki Y, et al. 2016. PLoS One. 11: 0158282. PubMed
  33. Leach SM, et al. 2020. Cell Rep. 33:108337. PubMed
  34. Uzhachenko RV, et al. 2021. Cell Reports. 35(1):108944. PubMed
  35. Christian LS, et al. 2021. Cell Reports. 35(6):109118. PubMed
  36. Dong L, et al. 2021. Cancer Cell. . PubMed
  37. Castiello MC, et al. 2020. J Allergy Clin Immunol. . PubMed
  38. Wang D, et al. 2018. Immunity. 48:659. PubMed
  39. Misumi I et al. 2019. Cell Rep. 27(5):1387-1396 . PubMed
  40. Song C, et al. 2019. Nat Commun. 10:3745. PubMed
  41. Takeda Y, et al. 2018. Innate Immun. 24:323. PubMed
  42. Gupta SS, et al. 2019. Cell Rep. 29:1862. PubMed
  43. Riley JS, et al. 2020. Blood Adv. 4:1102. PubMed
  44. Mayer RL, et al. 2022. Nat Commun. 13:6075. PubMed
  45. Mirshahi F, et al. 2022. Cell Rep. 38:110454. PubMed
  46. del Rio ML, et al. 2021. Transl Res. Online ahead of print.. PubMed
  47. Tian H, et al. 2022. Cancer Sci. 113:875. PubMed
  48. Zhao J, et al. 2022. J Nanobiotechnology. 20:62. PubMed
  49. Fu Y, et al. 2020. Mol Ther. 1214:28. PubMed
  50. Hirano KI, et al. 2021. eLife. 0.416666666666667. PubMed
  51. Delacher M, et al. 2021. Immunity. 54(4):702-720.e17. PubMed
  52. Zheng H, et al. 2021. Frontiers in Cell and Developmental Biology. 9:641527. PubMed
  53. Blumenthal D, et al. 2020. eLife. 9:e55995.. PubMed
  54. Chakrabarti J, et al. 2018. Oncotarget. 9:37439. PubMed
  55. Yuzhu Hou et al. 2018. Immunity. 49(3):490-503 . PubMed
  56. Oyarce C, et al. 2018. Front Immunol. 8:1794. PubMed
  57. Bommireddy R, et al. 2020. Vaccines (Basel). 8:. PubMed
  58. Yin Y, et al. 2021. ACS Nano. 15:14347. PubMed
  59. Xu F, et al. 2022. Cell Death Discov. 8:142. PubMed
  60. Felker A, Croy B 2016. J Leukoc Biol. 100: 645 - 655. PubMed
  61. Wagner V, et al. 2016. Sci Transl Med. 8: 366ra164. PubMed
  62. He C, et al. 2020. Clin Transl Med. 10:e39. PubMed
  63. Pan H, et al. 2020. Mol Psychiatry. . PubMed
  64. Chen S et al. 2018. Cell reports. 25(7):1729-1740 . PubMed
  65. Hayatsu N et al. 2017. Immunity. 47(2):268-283 . PubMed
  66. Misumi I et al. 2019. Cell Rep. 27(2):514-524 . PubMed
  67. Zhang F, et al. 2019. Nat Commun. 10:3974. PubMed
  68. Lee JH, et al. 2018. Transgenic Res. 27:241. PubMed
  69. Demircioglu F, et al. 2020. Nat Commun. 11:1290. PubMed
  70. Guo H, et al. 2022. PLoS Pathog. 18:e1010857. PubMed
  71. Frey N, et al. 2022. Nat Commun. 13:1804. PubMed
  72. Zhang J, et al. 2022. Front Immunol. 13:931740. PubMed
  73. Bhattacharya P, et al. 2022. PLoS Negl Trop Dis. 16:e0010224. PubMed
  74. Zhan Y, et al. 2021. JCI Insight. 6:. PubMed
  75. Zhan CS, et al. 2020. FASEB J. 14006:34. PubMed
  76. Mitchell JE, et al. 2021. Cell Reports. 35(2):108966. PubMed
  77. Han C, et al. 2021. Cell Reports. 34(6):108706. PubMed
  78. Lebratti T, et al. 2021. eLife. 10:00. PubMed
  79. Eriksson E, et al. 2016. Gene Ther. 10.1038/gt.2016.80. PubMed
  80. Shade K, et al. 2015. J Exp Med. 212:457. PubMed
  81. Zhang C, et al. 2020. Cell Metabolism. 31(1):148-161.e5.. PubMed
  82. Lu Y, et al. 2020. Cell. 180(6):1081-1097. PubMed
  83. Uchimura T et al. 2018. Immunity. 49(6):1049-1061 . PubMed
  84. Li Y, et al. 2019. Oncol Rep. 41:2679. PubMed
  85. Tran L, et al. 2017. Cancer Immunol Res. 5:1141. PubMed
  86. Wang L, et al. 2021. Cancer Immunol Res. 9:348. PubMed
  87. Si L, et al. 2022. Nat Biotechnol. 40:1370. PubMed
  88. Ebina-Shibuya R, et al. 2021. Elife. 10:. PubMed
  89. Yin Q, et al. 2015. PLoS One. 10: 0137808. PubMed
  90. Vieyra-Garcia P, et al. 2016. Clin Cancer Res. 22: 3328 - 3339. PubMed
  91. Matsumura K, et al. 2016. J Immunol. 197: 3233 - 3244. PubMed
  92. Paiva RA, et al. 2021. Cell Reports. 35(2):108967. PubMed
  93. Solanki A, et al. 2018. Development. 145. PubMed
  94. Koliaraki V et al. 2019. Cell reports. 26(3):536-545 . PubMed
  95. Zhang F, et al. 2019. Immunity. 50:738. PubMed
  96. Riffelmacher T et al. 2017. Immunity. 47(3):466-480 . PubMed
  97. Caronni N, et al. 2018. Cancer Res. 78:1685. PubMed
  98. He X, et al. 2021. Small. 17:e2007165. PubMed
  99. Pervaiz N, et al. 2021. Pigment Cell Melanoma Res. 34:918. PubMed
  100. Katsinas N, et al. 2022. J Clin Med. 11:. PubMed
  101. He X, et al. 2021. Adv Sci (Weinh). 8:e2103023. PubMed
  102. Jeong SH, et al. 2021. Nat Commun. 12:4405. PubMed
  103. Huang Y, et al. 2020. FASEB J. 34:1768. PubMed
  104. Aegerter H, et al. 2020. Nat Immunol. 0.975694444. PubMed
  105. Poczobutt J, et al. 2016. J Immunol. 196: 891 - 901. PubMed
  106. Brummer G, et al. 2020. Oncogene. 39:2275. PubMed
  107. Maluski M, et al. 2019. J Clin Invest. 129:5108. PubMed
  108. Soldevilla MM, et al. 2019. Mol Ther. 27:1878. PubMed
  109. Liu D et al. 2019. Immunity. 51(1):64-76 . PubMed
  110. Luo Y et al. 2019. Cell reports. 26(7):1869-1879 . PubMed
  111. Miska J et al. 2019. Cell reports. 27(1):226-237 . PubMed
  112. Liu J, et al. 2019. J Exp Med. 216:656. PubMed
  113. Funk KE, et al. 2019. J Neuroinflammation. 16:22. PubMed
  114. Cong J et al. 2018. Cell metabolism. 28(2):243-255 . PubMed
  115. Divan A, et al. 2018. PLoS One. 13:e0196893. PubMed
  116. Alikhanyan K, et al. 2021. Cancers (Basel). 13:. PubMed
  117. Chen Q, et al. 2016. Nat Commun. 7:13193. PubMed
  118. Hoefflin R, et al. 2020. Nat Commun. 3.313194444. PubMed
  119. Espinosa JR, et al. 2018. Front Immunol. 9:1371. PubMed
  120. Lee JS et al. 2018. Cell. 174(6):1559-1570 . PubMed
  121. Schadt L, et al. 2020. Cell Reports. 29(5):1236-1248.e7.. PubMed
  122. Zheng Z, et al. 2020. Cell Death Dis. 0.684722222. PubMed
  123. Xu H, et al. 2020. Immunity. 51(4):696-708.e9.. PubMed
  124. Zhao X, et al. 2022. Nat Protoc. 17:2240. PubMed
  125. He X, et al. 2022. Cancer Immunol Res. 10:314. PubMed
  126. Liu T, et al. 2022. Front Immunol. 13:901349. PubMed
  127. Zhang C, et al. 2022. Nat Commun. 13:3468. PubMed
  128. Goldfarb Y, et al. 2021. J Exp Med. 218:. PubMed
  129. Ye P, et al. 2022. Front Cardiovasc Med. 8:810477. PubMed
  130. Chen G, et al. 2021. Sci Adv. 7:eabg5686. PubMed
  131. Tartey S, et al. 2021. Cancer Research. 81(9):2358-2372. PubMed
  132. Elahi S, et al. 2020. Stem Cell Res. 43:101710. PubMed
  133. Bayik D, et al. 2020. Cancer Discov. 1.256944444. PubMed
  134. Yi X, et al. 2020. Sci Adv. 6:eaba3546. PubMed
  135. Vidy A, et al. 2016. PLoS One. 11:e0165361. PubMed
  136. Mirando AC, et al. 2020. Oncoimmunology. 9:1760685. PubMed
  137. Horiguchi H, et al. 2019. Genes Dev. 33:1641. PubMed
  138. Bai C, et al. 2020. Mol Ther Oncolytics. 17:9. PubMed
  139. Leal AS, et al. 2019. Sci Rep. 5.286111111. PubMed
  140. Al–Zaher AA, et al. 2018. Mol Ther Oncolytics. 0.376388889. PubMed
  141. Li W, et al. 2019. Nat Commun. 10:3349. PubMed
  142. Budida R, et al. 2017. Eur J Immunol. 47:1819. PubMed
  143. Reismann D, et al. 2017. Nat Commun.. 10.1038/s41467-017-01538-9. PubMed
  144. Ishidome T et al. 2017. EBioMedicine. 22:89-99 . PubMed
  145. Oka Y, et al. 2020. Sci Adv. 6:. PubMed
  146. Haas MS, et al. 2020. Mol Cancer Res. 19:717. PubMed
  147. Jiang Y, et al. 2020. Adv Mater. 32:e2001808. PubMed
  148. Shannon JP, et al. 2021. STAR Protoc. 2:100790. PubMed
  149. Li H, et al. 2021. Nat Commun. 12:7149. PubMed
  150. Dey S, et al. 2020. J Immunother Cancer. 8:. PubMed
  151. Wu H, et al. 2021. Cell Death Discov. 7:225. PubMed
  152. Shen M, et al. 2022. Nat Cancer. 3:60. PubMed
  153. Zhang Q, et al. 2022. Nat Commun. 13:2406. PubMed
  154. Germundson DL, et al. 2022. Front Allergy. 3:870513. PubMed
  155. Li YN, et al. 2022. Nat Commun. 13:4074. PubMed
  156. Gibbins J, et al. 2014. Blood. 124:2953. PubMed
  157. Ku C, et al. 2015. Genes Dev. 29: 1930-1941. PubMed
  158. Cook KD, et al. 2015. Immunity. 43:703-714. PubMed
  159. Latasa C, et al. 2016. PLoS One. 11: 0161216. PubMed
  160. Holokai L, et al. 2020. Cancers (Basel). 12:00. PubMed
  161. Wanner-Seleznik GM, et al. 2020. Immunohorizons. 0.644444444. PubMed
  162. Zeng W, et al. 2021. STAR Protocols. 2(1):100361. PubMed
  163. Vaena S, et al. 2021. Cell Reports. 35(5):109076. PubMed
  164. Ren W, et al. 2018. Mucosal Immunol. 12:531. PubMed
  165. Hu J, et al. 2019. Mol Ther Nucleic Acids. 16:650. PubMed
  166. Matsuo K, et al. 2018. J Immunol. 200:800. PubMed
  167. Takaku S, et al. 2020. Integr Cancer Ther. 19:1534735419900798. PubMed
  168. Alikhanyan K, et al. 2020. Immun Inflamm Dis. 8:181. PubMed
  169. Medyouf H, et al. 2010. Blood. 115:1175. PubMed
  170. Yang Z, et al. 2021. Onco Targets Ther. 14:4239. PubMed
  171. Otvos B, et al. 2021. Clin Cancer Res. 27:2038. PubMed
  172. Ding P, et al. 2022. Bone Res. 10:42. PubMed
  173. Li Y, et al. 2021. Cell Death Dis. 12:1001. PubMed
  174. Bates PD, et al. 2021. Front Immunol. 12:668307. PubMed
  175. Shannon JP, et al. 2021. Immunity. 54(2):276-290.e5. PubMed
  176. Oguri Y, et al. 2020. Cell. 182(3):563-577.e20. PubMed
  177. Guo H, et al. 2014. J Leukoc Biol. 96:419. PubMed
  178. Lin W, et al. 2019. EBioMedicine. 49:133. PubMed
  179. Chen Z, et al. 2019. J Exp Med. 216:152. PubMed
  180. Nam GH, et al. 2018. Nat Commun. 9:2165. PubMed
  181. Chatterjee S et al. 2017. Cell metabolism. 27(1):85-100 . PubMed
  182. Hu Y, et al. 2021. Cell Death Dis. 12:743. PubMed
  183. Schreiber K, et al. 2020. Cancer Immunol Res. 8:192. PubMed
  184. Feng Y, et al. 2022. J Nanobiotechnology. 20:193. PubMed
  185. Sun S, et al. 2013. J Immunol. 190:6209. PubMed
  186. Wang H, et al. 2020. Nat Mater. 1.655555556. PubMed
  187. Nanou A, et al. 2021. Cell Reports. 35(8):109168. PubMed
  188. Lin YH, et al. 2018. Cancer Immunol Res. 0.25. PubMed
  189. Morelli AE, et al. 2020. Cell Rep. 30:3448. PubMed
  190. Zhang NN, et al. 2020. Cell. 182(5):1271-1283. PubMed
  191. Mohamed E, et al. 2020. Immunity. 52(4):668-682.e7.. PubMed
  192. Wang Y, et al. 2021. Nat Commun. 12:4964. PubMed
  193. Takahashi F, et al. 2022. iScience. 25:104278. PubMed
  194. Qi J, et al. 2021. Nat Commun. 12:4755. PubMed
  195. Robertson TF, et al. 2021. J Cell Biol. 220:. PubMed
  196. Nasarre P, et al. 2021. Cancers (Basel). 13: . PubMed
  197. Li X, et al. 2021. Cell Death Dis. 12:314. PubMed
  198. Chen R, et al. 2021. Cell Reports. 34(7):108751. PubMed
  199. Alexandre YO, et al. 2020. Cell Reports. 33(13):108567. PubMed
  200. Nahrendorf W, et al. 2021. eLife. 10:00. PubMed
  201. Gong N, et al. 2020. Nat Nanotechnol. 1.35625. PubMed
  202. Wu L, et al. 2020. Cell Rep. 33:108327. PubMed
  203. Swanson P, et al. 2016. PLoS Pathog. 12:e1006022. PubMed
  204. Teo T, et al. 2015. J Virol. 89: 7955-7969. PubMed
  205. Sasaki Y, et al. 2015. PLoS One. 10: 0131176. PubMed
  206. Spangenberg E, et al. 2019. Nat Commun. 10:3758. PubMed
  207. Frazer GL, et al. 2021. J Cell Biol. 220:. PubMed
  208. Do-Thi VA, et al. 2021. Cancers (Basel). 13:. PubMed
  209. Wang J, et al. 2022. Clin Transl Med. 12:e718. PubMed
  210. Kataru RP, et al. 2022. Front Aging. 3:864860. PubMed
  211. Zhao X, et al. 2022. iScience. 25:104690. PubMed
  212. Huber MK, et al. 2021. J Vis Exp. :. PubMed
  213. Chen H, et al. 2022. Front Pharmacol. 13:827520. PubMed
  214. Ma Q, et al. 2022. Vaccines (Basel). 10:. PubMed
  215. Fonderflick L, et al. 2022. Cells. 11:. PubMed
  216. Rao L, et al. 2020. Nat Commun. 11:4909. PubMed
  217. Murata T, et al. 2020. Sci Rep. 10:13560. PubMed
  218. He X, et al. 2021. J Immunother Cancer. 9:. PubMed
  219. Zheng Z, et al. 2021. Nat Commun. 12:6202. PubMed
  220. Kiss M, et al. 2020. Cancer Immunol Res. 9:309. PubMed
  221. Dallari S, et al. 2021. Cell Host Microbe. 29(6):1014-1029.e8. PubMed
  222. Ulaganathan VK, et al. 2020. Sci Rep. 10:8453. PubMed
  223. Li X, et al. 2017. Front Immunol. 8:1186. PubMed
  224. Schuster M, et al. 2019. Front Immunol. 10:1583. PubMed
  225. Fang W, et al. 2021. J Exp Clin Cancer Res. 40:4. PubMed
  226. Zheng Z, et al. 2021. Biomed Res Int. 2021:5535578. PubMed
  227. Jiang Y, et al. 2021. Nat Commun. 12:742. PubMed
  228. Zhang Z, et al. 2020. Nature. 579:415. PubMed
  229. Harrison DK, et al. 2021. Transplantation. 105:540. PubMed
  230. Tassi I, et al. 2014. J Immunol. 193:4303. PubMed
  231. Kramer K, et al. 2017. Mol Ther. 25(1):62-70. PubMed
  232. Zheng DW, et al. 2020. Nat Commun. 3.865972222. PubMed
  233. Yin X, et al. 2020. Cell Rep. 33:108278. PubMed
  234. Lu C, et al. 2020. Cancer Cell. 39(1):96-108.e6. PubMed
  235. Gaya M et al. 2018. Cell. 172(3):517-533 . PubMed
  236. Zhang J, et al. 2018. Oncoimmunology. 7:e1461301. PubMed
  237. Yoshida H, et al. 2019. Cell. 176:897. PubMed
  238. Chao Y, et al. 2020. Sci Adv. 6:eaaz4204. PubMed
  239. Kataru RP, et al. 2019. Cancer Immunol Res. 7:1345. PubMed
  240. Liu YW, et al. 2022. JCI Insight. 7:. PubMed
  241. Sun Y, et al. 2022. iScience. 25:104846. PubMed
  242. Chen B, et al. 2021. Cell. 184:6262. PubMed
  243. Smith LK, et al. 2021. Elife. 10:. PubMed
  244. Nagatake T, et al. 2021. Int Immunol. 33:171. PubMed
  245. Tang-Huau TL, et al. 2021. Viruses. 13: . PubMed
  246. Ukidve A, et al. 2020. Proc Natl Acad Sci U S A. 117:17727. PubMed
  247. Pelly V, et al. 2016. Mucosal Immunol. 10.1038/mi.2016.4. PubMed
  248. Chen S, et al. 2015. Cancer Res . 7: 519-531. PubMed
  249. Chakraborty P, et al. 2020. Cell Reports. 28(7):1879-1893.e7.. PubMed
  250. Han P, et al. 2020. Sci Adv. 6:eaaz1580. PubMed
  251. Nakamura K, et al. 2018. Cancer Cell. 33:634. PubMed
  252. Tippimanchai DD, et al. 2018. Oncoimmunology. 7:e1438105. PubMed
  253. Cong L, et al. 2021. Breast Cancer Res. 23:51. PubMed
  254. Dourcy M, et al. 2020. Mucosal Immunol. 13:799. PubMed
  255. Zhou P, et al. 2022. Mol Ther Oncolytics. 25:236. PubMed
  256. Zheng Y, et al. 2022. Transl Res. :. PubMed
  257. Funk KE, et al. 2021. Aging Cell. 20:e13412. PubMed
  258. Tian T, et al. 2020. Cancer Immunol Res. 660:8. PubMed
  259. Konishi Y, et al. 2018. iScience. 10:98. PubMed
  260. Wang J, et al. 2020. J Hematol Oncol. 0.610416667. PubMed
  261. Zhang Y, et al. 2022. J Immunother Cancer. 10:. PubMed
  262. Bessell CA, et al. 2020. JCI Insight. 5:. PubMed
  263. Li C, et al. 2022. Front Cell Dev Biol. 10:913824. PubMed
  264. Tseng SH, et al. 2021. J Biomed Sci. 28:63. PubMed
  265. Li X, et al. 2021. Front Immunol. 12:779560. PubMed
  266. Galeano Nio JL, et al. 2020. eLife. 9:00. PubMed
  267. Liu WL, et al. 2019. Nat Commun. 10:3199. PubMed
  268. Johnson JL et al. 2018. Immunity. 48(2):243-257 . PubMed
RRID
AB_312750 (BioLegend Cat. No. 100711)
AB_312751 (BioLegend Cat. No. 100712)

Antigen Details

Structure
Ig superfamily, CD8α chain, 34 kD
Distribution

Most thymocytes, T cell subset, some NK cells, lymphoid dendritic cells

Function
Co-receptor for TCR
Ligand/Receptor
MHC class I molecule
Antigen References

1. Barclay A, et al. 1997. The Leukocyte Antigen FactsBook Academic Press.
2. Zamoyska R. 1994. Immunity 1:243.
3. Ellmeier W, et al. 1999. Annu. Rev. Immunol. 17:523.

Gene ID
12525 View all products for this Gene ID
UniProt
View information about CD8alpha on UniProt.org

Other Formats

View All CD8a Reagents Request Custom Conjugation
Description Clone Applications
APC anti-mouse CD8a 53-6.7 FC
Biotin anti-mouse CD8a 53-6.7 FC,IHC
FITC anti-mouse CD8a 53-6.7 FC
PE anti-mouse CD8a 53-6.7 FC
PE/Cyanine5 anti-mouse CD8a 53-6.7 FC
Purified anti-mouse CD8a 53-6.7 FC,CyTOF®,IHC-F,IP
PE/Cyanine7 anti-mouse CD8a 53-6.7 FC
APC/Cyanine7 anti-mouse CD8a 53-6.7 FC
Alexa Fluor® 488 anti-mouse CD8a 53-6.7 FC,3D IHC
Alexa Fluor® 647 anti-mouse CD8a 53-6.7 FC,IHC-F,3D IHC,SB
Pacific Blue™ anti-mouse CD8a 53-6.7 FC
Alexa Fluor® 700 anti-mouse CD8a 53-6.7 FC
PerCP/Cyanine5.5 anti-mouse CD8a 53-6.7 FC
PerCP anti-mouse CD8a 53-6.7 FC
Brilliant Violet 421™ anti-mouse CD8a 53-6.7 FC,IHC,SB
Brilliant Violet 570™ anti-mouse CD8a 53-6.7 FC
Brilliant Violet 650™ anti-mouse CD8a 53-6.7 FC
Brilliant Violet 605™ anti-mouse CD8a 53-6.7 FC
Ultra-LEAF™ Purified anti-mouse CD8a 53-6.7 FC,CyTOF®,IHC,IP,Depletion,Block
Brilliant Violet 711™ anti-mouse CD8a 53-6.7 FC
Brilliant Violet 785™ anti-mouse CD8a 53-6.7 FC
Brilliant Violet 510™ anti-mouse CD8a 53-6.7 FC
Purified anti-mouse CD8a (Maxpar® Ready) 53-6.7 FC,CyTOF®
Alexa Fluor® 594 anti-mouse CD8a 53-6.7 IHC-F,FC,3D IHC
PE/Dazzle™ 594 anti-mouse CD8a 53-6.7 FC
APC/Fire™ 750 anti-mouse CD8a 53-6.7 FC
GoInVivo™ Purified anti-mouse CD8a 53-6.7 FC
TotalSeq™-A0002 anti-mouse CD8a 53-6.7 PG
Spark Blue™ 550 anti-mouse CD8a 53-6.7 FC
Spark NIR™ 685 anti-mouse CD8a 53-6.7 FC
TotalSeq™-C0002 anti-mouse CD8a 53-6.7 PG
TotalSeq™-B0002 anti-mouse CD8a 53-6.7 PG
Spark YG™ 570 anti-mouse CD8a 53-6.7 IHC-F
PE/Fire™ 640 anti-mouse CD8a 53-6.7 FC
PE/Fire™ 700 anti-mouse CD8a 53-6.7 FC
Spark Blue™ 574 anti-mouse CD8a Antibody 53-6.7 FC
Spark Violet™ 423 anti-mouse CD8a Antibody 53-6.7 FC
Spark UV™ 387 anti-mouse CD8a 53-6.7 FC
Spark Blue™ 515 anti-mouse CD8a 53-6.7 FC
APC/Fire™ 810 anti-mouse CD8a 53-6.7 FC
Spark Red™ 718 anti-mouse CD8a (Flexi-Fluor™) 53-6.7 FC
Spark PLUS UV™ 395 anti-mouse CD8a 53-6.7 FC
Go To Top Version: 2    Revision Date: 01/21/2014

For Research Use Only. Not for diagnostic or therapeutic use.

 

This product is supplied subject to the terms and conditions, including the limited license, located at www.biolegend.com/terms) ("Terms") and may be used only as provided in the Terms. Without limiting the foregoing, BioLegend products may not be used for any Commercial Purpose as defined in the Terms, resold in any form, used in manufacturing, or reverse engineered, sequenced, or otherwise studied or used to learn its design or composition without express written approval of BioLegend. Regardless of the information given in this document, user is solely responsible for determining any license requirements necessary for user’s intended use and assumes all risk and liability arising from use of the product. BioLegend is not responsible for patent infringement or any other risks or liabilities whatsoever resulting from the use of its products.

 

BioLegend, the BioLegend logo, and all other trademarks are property of BioLegend, Inc. or their respective owners, and all rights are reserved.

 

8999 BioLegend Way, San Diego, CA 92121 www.biolegend.com
Toll-Free Phone: 1-877-Bio-Legend (246-5343) Phone: (858) 768-5800 Fax: (877) 455-9587

This data display is provided for general comparisons between formats.
Your actual data may vary due to variations in samples, target cells, instruments and their settings, staining conditions, and other factors.
If you need assistance with selecting the best format contact our expert technical support team.

ProductsHere
Login / Register
Remember me
Forgot your password? Reset password?
Create an Account